Uncategorized
Aerie reports quarterly net loss of $13.1 million
Aerie Pharmaceuticals reported a net loss of $13.1 million, or $0.54 per share, in the third quarter, compared with a loss of $10.9 million, or $10.81 per share, in the third quarter 2013 when the company was privately held, according to a press release.The net loss was attributed to higher operating expenses related to more clinical and nonclinical activities for Rhopressa, more nonclinical activities for Roclatan and an increase in supporting growth in operations.